ARTICLE | Company News

Isotechnika, 3SBio deal

August 30, 2010 7:00 AM UTC

Isotechnika granted 3SBio exclusive rights to develop and commercialize voclosporin for transplant and autoimmune indications in China, including Hong Kong and Taiwan. Voclosporin, a transisomer of a cyclosporine analog that inhibits calcineurin, has completed Phase IIb testing to prevent kidney rejection following transplant. 3SBio will be responsible for clinical development, registration and commercialization of voclosporin in China. Isotechnika will provide commercial supply to 3SBio under a separate agreement. ...